ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1753 • ACR Convergence 2023

    Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint

    Georgios Vasileiadis1, Anna-Karin Hultgård Ekwall2, Reshmi Sureshkumar1, Monica Guma3, Anna Rudin4, Yuan Zhang1 and Cristina Maglio1, 1Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, 3San Diego VA Healthcare Service, La Jolla, CA, 4Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Several metabolic pathways have been implicated in rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) aggressive phenotype1,2. Here, we aimed to analyse the full spectrum of…
  • Abstract Number: 2003 • ACR Convergence 2023

    Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis

    Ruban Dhaliwal1, John Boxberger2, Yamei Wang2, Bruce Mitlak2, Ludovic Humbert3 and Neil Binkley4, 1Massachusetts General Hospital, Boston, MA, 2Radius Health, Inc., Boston, MA, 33D-Shaper Medical, Barcelona, Spain, 4University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI

    Background/Purpose: Abaloparatide (ABL) increases BMD in men with osteoporosis. In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) trial, DXA-measured BMD change with…
  • Abstract Number: 2008 • ACR Convergence 2023

    Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Jeffrey Curtis1, Tarun Arora2, Ye Liu1, Tzu-Chieh Lin3, Leslie Spangler3, Vanessa C. Brunetti3, Robert K. Stad3, Michele McDermott3, Brian D. Bradbury3 and Min Kim3, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…
  • Abstract Number: 1747 • ACR Convergence 2023

    A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells

    Adela Navratilova1, Klára Prajzlerová2, Nora Růžičková3, Karel Pavelka4, Jiri Vencovsky5, Ladislav Senolt6, Maria Filkova3 and Lucie Andrés Cerezo3, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 5Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: Interleukin-40 (IL-40) is a newly described cytokine related to malignancies and immunity function. We have previously shown that IL-40 is up-regulated in early stages…
  • Abstract Number: 1744 • ACR Convergence 2023

    Histological and Molecular Comparison in the Synovial Tissue of Patients with Active Rheumatoid Arthritis to Remission

    Selina Ohl1, Klaus Frommer1, Markus Rickert2, Stefan Rehart3, Ulf Müller-Ladner1 and Elena Neumann1, 1Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 2Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, 3Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which leads to local and systemic manifestations. Subsequently, the inflamed synovium drives the destruction of…
  • Abstract Number: 1674 • ACR Convergence 2023

    Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group

    Benjamin de Valence de Minardiere1, Marion Delaune2, Yann Nguyen3, Vincent Jachiet4, Mael Heiblig5, Alexis Jean6, Pierrick Henneton7, stanislas Riescher-tuczkiewicz8, Philippe Guilpain7, Hervé Lobbes9, Guillaume Le Guenno10, Nicolas Schleinitz11, Valentin Lacombe12, Vincent Langlois13, Roderau Outh14, Julien Vinit15, Jean-Philippe Martellosio16, Paul Decker17, Alexandre Vlakos18, Thomas Moulinet19, Yannick Dieudonne20, Adrien Bigot21, Louis Terriou22, Bertrand De Maleprade23, Guillaume Denis24, Jonathan Broner25, Marie Kostine26, Sébastien Humbert27, Benjamin Terrier28, Sophie Georgin-Lavialle29, Olivier Fain30, Arsène Mekinian1, Marjolaine MORGAND1, Thibault Comont2 and Jerome Hadjadj1, 1Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, 2Toulouse University Hospital, Toulouse, France, 3Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 4Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France, 5Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France, 6Internal Medicine Department, Bordeaux University, Faculty of Medicine, Bordeaux University Hospital, Bordeaux, France, 7CHU Montpellier, Montpellier, France, 8CHU de Nantes, Nantes, France, 9CHU de Clermont-Ferrand, Clermont-Ferrand, France, 10Internal Medicine Department, Clermont-Ferrand University, Faculty of Medicine, Estaing University Hospital, Clermont-Ferrand, France, 11Aix Marseille university, AP-HM, Marseille, France, 12Internal Medicine Department, Anger Hospital, Clermont-Ferrand, France, 13Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France, 14Internal Medicine Department, Perpignan Hospital Center, Perpignan, France, 15Service de Médecine Interne, CH William Morey, Chalon sur Saône, France., Chalon sur Saône, France, 16Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, 17Nancy hospital, France, Nancy, France, 18Vesoul Hospital, Vesoul, France, 19Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, 20Department of Clinical Immunology and Internal Medicine, National Reference Centre for Systemic Autoimmune Diseases (CNR RESO), Strasbourg University Hospital, Strasbourg, France, 21Internal Medicine Department, Tours University, Faculty of Medicine, Tours University Hospital, Tours, France, 22Service de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France, 23Rouen hospital, France, Rouen, France, 24Service d'hématologie, CH de Rochefort, Rochefort, France, 25CHU de Nimes, Nimes, France, 26Bordeaux University Hospital, Bordeaux, France, 27Besançon University Hospital, Besançon, France, 28Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, 29AP-HP, Tenon hospital, Paris, France, 30Hopital SAINT ANTOINE APHP, Paris, France

    Background/Purpose: VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory monogenic disease caused by inactivating somatic mutations in the UBA1 gene and characterized…
  • Abstract Number: 2007 • ACR Convergence 2023

    Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study

    Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY

    Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
  • Abstract Number: 2006 • ACR Convergence 2023

    Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic

    Massiel Jimenez Artiles1, Roshan Subedi2, Qi Wang3, Bishara Jahshan4, Khalid Gadir4 and Waleed Quwatli5, 1Unity Hospital, Rochester Regional Health, Greece, NY, 2Rochester Regional Health/Unity Hospital, Greece, NY, 3Rochester Regional Health/Unity Hospital, Rochester, NY, 4Unity Hospital, Rochester Regional Health, Rochester, NY, 5Unity Hospital/ Rochester Regional Health, Rochester, NM

    Background/Purpose: Osteoporotic fractures, especially hip fractures, are associated with significant morbidity, including limitations in ambulation, disability, and decreased quality of life. The aim of this…
  • Abstract Number: 1755 • ACR Convergence 2023

    Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes

    Camilla R. L. Machado1, David Boyle1, Narayanan B. Perumal2, Robert J. Benschop3 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2Eli Lilly and Company, San Diego, CA, 3Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: The synovial lining of rheumatoid arthritis (RA) is formed by a network of fibroblast-like synoviocytes (FLS). Cadherins are type I transmembrane proteins and participate…
  • Abstract Number: 1746 • ACR Convergence 2023

    Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies

    Tineke van Wesemael1, Anna Svärd2, Annemarie Dorjee1, Thomas Huizinga1, René Toes1 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Centre for Clinical Research Dalarna, Uppsala, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
  • Abstract Number: 1658 • ACR Convergence 2023

    Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis

    Chrissy Bolton1, Christopher Mahony2, Charlotte Smith2, Vicky Alexiou3, Huong Nguyen3, Patricia Reis-Nisa2, Søren Lomholt4, Annie Hackland2, Sugrah Sultan5, Klaudia Kupiec3, Sunit Davda6, Charlene Foley6, Calliope Dendrou1, Elizabeth C Rosser7, Accelerating Medicines Partnership Program RA SLE Network8, Anna Helena Jonsson9, Fan Zhang10, Michael Brenner11, Soumya Raychaudhuri9, Christopher Buckley1, Manigandan Thyagarajan5, Zishan Shiekh5, Sandrine Compeyrot-Lacassagne6, Samantha Chippington6, Mark Coles1, Eslam Al-Abadi5, Andrew Filer2, Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium12, Lucy R Wedderburn3 and Adam Croft2, 1University of Oxford, Oxford, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3UCL Great Ormond Street Institute of Child Health, London, United Kingdom, 4Aarhus University, Aarhus, Denmark, 5Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, 6Great Ormond Street Hospital, London, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Brigham and Women's Hospital, Boston, MA, 10University of Colorado, Aurora, CO, 11Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 12MRC, Birmingham, United Kingdom

    Background/Purpose: Understanding the unique and shared pathogenic processes between childhood-onset and adult-onset inflammatory arthritides is needed to guide more effective drug development and their application…
  • Abstract Number: 1667 • ACR Convergence 2023

    Characterization of the Vascular Niches in Systemic Sclerosis (SSc) as a Prototypical Immune-mediated Fibrotic Disease with Prominent Vasculopathy Using Imaging Mass Cytometry

    Minrui Liang1, Aleix Rius Rigau2, yi-nan Li1 and Joerg Distler1, 1Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 2Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie (DZI), FAU Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Systemic sclerosis (SSc) is a prototypical collagen-vascular disease with prominent vasculopathy. Although microvascular changes are the earliest histopathologic manifestation of SSc, the vascular dysregulation…
  • Abstract Number: 1042 • ACR Convergence 2023

    B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis

    Shinji Watanabe1, Keina Yomono2, Shintaro Yamamoto1, Mikito Suzuki3, Takahisa Gono4 and Masataka Kuwana4, 1Nippon Medical School, Tokyo, Japan, 2Nippon Medical School University, Tokyo, Japan, 3Nippon Medical School Hospital, Tokyo, Japan, 4Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Lung ultrasound (LUS) is a non-invasive imaging tool to evaluate distribution and severity of interstitial lung disease (ILD). Utility of LUS has been examined…
  • Abstract Number: 1466 • ACR Convergence 2023

    Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020

    Shreena Kamlesh Gandhi1, Abhiram Challa2, Sandhya Shri Kanniyaram3, Arnav Kamat4, Tejasri Polana5 and Kaleb Michaud6, 1Kansas University School of Medicine, Wichita, KS, 2KU School of Medicine, Wichita, KS, 3John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 4NYCH+H/Woodhull, New York, NY, 5Jawaharlal Nehru Medical College, Belgaum, Belgaum, India, 6University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…
  • Abstract Number: 1478 • ACR Convergence 2023

    Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review

    Alain Sanchez-Rodriguez1, Mariana Gonzalez-Treviño1, Hannah Langenfeld2, Cynthia Crowson3, Maria Valenzuela-Almada4, Alejandro Rabinstein5, Larry J. Prokop6, Isabel Valenzuela-Almada7 and Ali Duarte-Garcia3, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Department of Pediatrics, Children’s National Medical Center, Washington, DC, 5Department of Neurology, Mayo Clinic, Rochester, MN, 6Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, 7Division of Internal Medicine, Hospital Medica Sur, Mexico City, Mexico

    Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…
  • « Previous Page
  • 1
  • …
  • 427
  • 428
  • 429
  • 430
  • 431
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology